Video
Author(s):
With the population aging, there is a need for more home environmental treatment options for patients with kidney disease.
With the population aging and more and more people staying home because of the threat of COVID-19, at home dialysis options are crucial moving forward.
During the 2022 American Society of Nephrology (ASN) Annual Meeting in Orlando, investigators from Outset Medical presented new data on the Tablo Hemodialysis System, a dialysis system that can be used either at home or in a healthcare setting.
In an interview with HCPLive®, Cynthia Silva, MD, Medical Officer, Outset Medical, explained why it is important to have this option for patients in 2022.
“It is incredibly important now, especially across the healthcare sector, moving into the home environment,” Silva said. “I think we are seeing this move to home and it is also very patient focused. Whether you live in an urban area or a very rural area, you have access to the same level of care.”
In the study, investigators compared real world data from the Tablo system to the results of the IDE trial. The results show treatment adherence was 95% with 92% of treatments completing at least 90% of the prescribed time.
Real-World Study Confirms Similar Efficacy of Guselkumab and IL-17i for PsA